Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism

Neurobiology of Disease

Volumn 30, Issue 3, 2008, Pages 430-438

  Viaro, Riccardo ^a   Sanchez Pernaute, Rosario ^b,c   Marti, Matteo ^a   Trapella, Claudio ^a   Isacson, Ole ^b,c   Morari, Michele ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

J 113397; L DOPA; MPTP; Nociceptin orphanin FQ; NOP receptor; NOP mice; Parkinson's disease

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; NOCICEPTIN; NOCICEPTIN RECEPTOR;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HYPOKINESIA; LOW DRUG DOSE; MACACA; MALE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL;

ANIMALS; BENZIMIDAZOLES; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED C57BL; MOTOR SKILLS; MPTP POISONING; PIPERIDINES; RECEPTORS, OPIOID;

EID: 43649104203     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.02.011     Document Type: Article

References (37)

1. Bridge K.E., Wainwright A., Reilly K., and Oliver K.R. Autoradiographic localization of (125)i[Tyr(14)] nociceptin/orphanin FQ binding sites in macaque primate CNS. Neuroscience 118 (2003) 513-523
2. 2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br. J. Pharmacol. 136 (2002) 303-311
3. Chiou L.C., Liao Y.Y., Fan P.C., Kuo P.H., Wang C.H., Riemer C., and Prinssen E.P. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr. Drug Targets 8 (2007) 117-135
4. Cox B.M., Chavkin C., Christie M.J., Civelli O., Evans C., Hamon M.D., Hoellt V., Kieffer B., Kitchen I., Mcknight A.T., Meunier J.C., and Portoghese P.S. Opioid receptors. In: Girdlestone D. (Ed). The IUPHAR Compendium of Receptor Characterization and Classification (2000), IUPHAR Media Ltd, London
5. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
6. Devine D.P., Taylor L., Reinscheid R.K., Monsma F.J.J., Civelli O., and Akil H. Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ. Neurochem. Res. 21 (1996) 1387-1396
7. Florin S., Suaudeau C., Meunier J.C., and Costentin J. Nociceptin stimulates locomotion and exploratory behaviour in mice. Eur. J. Pharmacol. 317 (1996) 9-13
8. Gavioli E.C., Marzola G., Guerrini R., Bertorelli R., Zucchini S., De Lima T.C., Rae G.A., Salvadori S., Regoli D., and Calò G. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effect: pharmacological and genetic evidences from the mouse forced swimming test. Eur. J. Neurosci. 17 (2003) 1987-1990
9. Jackson-Lewis V., and Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2 (2007) 141-151
10. Jenck F., Wichmann J., Dautzenberg F.M., Moreau J.L., Ouagazzal A.M., Martin J.R., Lundstrom K., Cesura A.M., Poli S.M., Roever S., Kolczewski S., Adam G., and Kilpatrick G. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4938-4943
11. Jenkins B.G., Sanchez-Pernaute R., Brownell A.L., Chen Y.C., and Isacson O. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J. Neurosci. 24 (2004) 9553-9560
12. Kato H., Kurosaki R., Oki C., and Araki T. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res. 1030 (2004) 66-73
13. Kawamoto H., Ozaki S., Itoh Y., Miyaji M., Arai S., Nakashima H., Kato T., Ohta H., and Iwasawa Y. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[3R, 4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one (J-113397). J. Med. Chem. 42 (1999) 5061-5063
14. Ko M.C., Wie H., Woods J.H., and Kennedy R.T. Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies. J. Pharmacol. Exp. Ther. 318 (2006) 1257-1264
15. Koizumi M., Sakoori K., Midorikawa N., and Murphy N.P. The NOP (ORL1) receptor antagonist Compound B stimulates mesolimbic dopamine release and is rewarding in mice by a non-NOP-receptor-mediated mechanism. Br. J. Pharmacol. 143 (2004) 53-62
16. Kuzmin A., Sandin J., Terenius L., and Ogren S.O. Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors. Br. J. Pharmacol. 141 (2004) 132-140
17. Marti M., Mela F., Veronesi C., Guerrini R., Salvadori S., Federici M., Mercuri N.B., Rizzi A., Franchi G., Beani L., Bianchi C., and Morari M. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J. Neurosci. 24 (2004) 6659-6666
18. Marti M., Mela F., Guerrini R., Calò G., Bianchi C., and Morari M. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J. Neurochem. 91 (2004) 1501-1504
19. Marti M., Mela F., Fantin M., Zucchini S., Brown J.M., Witta J., Di Benedetto M., Buzas B., Reinscheid R.K., Salvadori S., Guerrini R., Romualdi P., Candeletti S., Simonato M., Cox B.M., and Morari M. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J. Neurosci. 95 (2005) 9591-9601
20. Marti M., Trapella C., Viaro R., and Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-Dopa additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J. Neurosci. 27 (2007) 1297-1307
21. Meredith G.E., and Kang U.J. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov. Disord. 21 (2006) 1595-1606
22. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B., Mazarguil H., Vassart G., Parmentier M., and Costentin J. Isolation and structure of the endogenus agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
23. Neal C.R.J., Akil H., and Watson S.J. Expression of orphanin FQ and the opioid receptor-like (ORL1) receptor in the developing human and rat brain. J. Chem. Neuroanat. 22 (2001) 219-249
24. Nishi M., Houtani T., Noda Y., Mamiya T., Sato K., Doi T., Kuno J., Takeshima H., Nukada T., Nabeshima T., Yamashita T., Noda T., and Sugimoto T. Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphanin FQ receptor. EMBO J. 16 (1997) 1858-1864
25. Okuyama S., Imagawa Y., Sakagawa T., Nakazato A., Yamaguchi K., Katoh M., Yamada S., Araki H., and Otomo S. NE-100, a novel sigma receptor ligand: effect on phencyclidine-induced behaviors in rats, dogs and monkeys. Life Sci. 55 (1994) PL133-PL138
26. Petzinger G.M., Walsh J.P., Akopian G., Hogg E., Abernathy A., Arevalo P., Turnquist P., Vucković M., Fisher B.E., Togasaki D.M., and Jakowec M.W. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J. Neurosci. 27 (2007) 5291-5300
27. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma F.J., and Civelli O. Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 270 (1995) 792-794
28. Rizzi A., Gavioli E.C., Marzola G., Spagnolo B., Zucchini S., Ciccocioppo R., Trapella C., Regoli D., and Calò G. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H benzocyclohepten-5-ol]: in vivo studies. J. Pharmacol. Exp. Ther. 32 (2007) 968-974
29. Rozas G., Guerra M.J., and Labandeira-Garcia J.L. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res. Protoc. 2 (1997) 75-84
30. Sakoori K., and Murphy N.P. Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice. Psychopharmacology 172 (2004) 129-136
31. Sanberg P.R., Bunsey M.D., Giordano M., and Norman A.B. The catalepsy test: its ups and downs. Behav. Neurosci. 102 (1988) 748-759
32. Sanchez-Pernaute R., Jenkins B.G., Choi J.K., Iris Chen Y.G., and Isacson O. In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias. Neurobiol. Dis. 27 (2007) 220-227
33. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K.W. MPTP susceptibility in the mouse: behavioural, neurochemical and histological analysis of gender and strain differences. Behav. Genet. 30 (2000) 171-182
34. Sedelis M., Schwarting R.K.W., and Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125 (2001) 109-125
35. Varty G.B., Hyde L.A., Hodgson R.A., Lu S.X., McCool M.F., Kazdoba T.M., Del Vecchio R.A., Guthrie D.H., Pond A.J., Grzelak M.E., Xu X., Korfmacher W.A., Tulshian D., Parker E.M., and Higgins G.A. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psycopharmacology (Berl.) 182 (2005) 132-143
36. Viaro R., Marti M., Morari M., and Franchi G. Nociceptin/orphanin FQ receptors modulate locomotion and motor cortex excitability in adult rats. Acta Physiol. 188 (2006) 5
37. Watanabe Y., Kato H., and Araki T. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease. Metab. Brain Dis. 23 (2008) 51-69